# US 10,869,843 B2 · Method for increasing muscle mass and strength

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,869,843 B2
- Document ID: US10869843B2
- Status: Granted
- Kind: B2
- Application number: 13/373,649
- Filed: 2011-11-23
- Published: 2012-06-07
- Granted: 2020-12-22
- Earliest claimed: 2010-11-23
- Assignees: Chemi Nutra, LLC
- Applicants: Lorenzo De Ferra; Marvin Heuer; Scott Hagerman; Martin Purpura; Ralf Jager
- Inventors: Lorenzo De Ferra; Marvin Heuer; Scott Hagerman; Martin Purpura; Ralf Jager
- Web page: https://patentgrep.com/patent/US10869843B2

## CPC

- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/661: Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion {or mevinphos}
- A61K 31/685: one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A61K 33/06: Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay}
- A61K 33/24: Heavy metals; Compounds thereof
- A61K 35/20: Milk; Whey; Colostrum
- A61K 38/014: {from connective tissue peptides, e.g. gelatin, collagen}
- A61K 38/1709: {from mammals}
- A61K 38/27: Growth hormone [GH], i.e. somatotropin
- A61K 38/28: Insulins
- A61K 38/30: Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 {(insulin-like growth factor binding protein A61K38/1754)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 21/06: Anabolic agents (androgens A61P5/26)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Phosphatidic acid is administered orally to increase muscle mass and strength in exercising mammals. Phosphatidic acid is administered orally to aging, bedridden or cachectic patients to improve nitrogen balance. The preferred form of phosphatidic acid for administration is phosphatidic acid-enriched lecithin. Creatine is co-administered orally to increase the muscle-building and strength effect. Other suggested additives include nutritional and herbal supplements, micronutrients and hormones.

## Claims

### Claim 1

A method of increasing muscle mass and strength in a subject, the method consisting of orally administering to a healthy exercising subject a therapeutically effective dose consisting of phosphatidic acid in the absence of creatine, wherein the therapeutically effective dose is 0.1 grams to 40 grams, and wherein the muscle strength of the subject increases by at least 10% after six weeks of resistance training, compared to the muscle strength of a similarly trained subject that does not ingest the effective dose of phosphatidic acid.

### Claim 2

A method of increasing muscle mass and strength in a subject, the method consisting of
orally administering to a healthy exercising subject a therapeutically effective dose consisting of phosphatidic acid in the absence of creatine, wherein the therapeutically effective dose is 0.1 grams to 40 grams, wherein the muscle strength of the subject increases by at least 10% after six weeks of resistance training, compared to the muscle strength of a similarly trained subject that does not ingest the effective dose of phosphatidic acid, and
orally administering to said healthy subject 20 grams to about 100 grams of collagen protein after exercise.

### Claim 3 (depends on 2)

The method of claim 2 wherein the effective dose of phosphatidic acid is about 800 mg per day.

### Claim 4 (depends on 1)

The method of claim 1, wherein the effective dose of phosphatidic acid is about 800 mg per day.